These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 31732678)

  • 1. Pretreatment
    Dissaux G; Visvikis D; Da-Ano R; Pradier O; Chajon E; Barillot I; Duvergé L; Masson I; Abgral R; Santiago Ribeiro MJ; Devillers A; Pallardy A; Fleury V; Mahé MA; De Crevoisier R; Hatt M; Schick U
    J Nucl Med; 2020 Jun; 61(6):814-820. PubMed ID: 31732678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentric development and evaluation of [
    Lucia F; Louis T; Cousin F; Bourbonne V; Visvikis D; Mievis C; Jansen N; Duysinx B; Le Pennec R; Nebbache M; Rehn M; Hamya M; Geier M; Salaun PY; Schick U; Hatt M; Coucke P; Hustinx R; Lovinfosse P
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1097-1108. PubMed ID: 37987783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PET/CT radiomics model for predicting distant metastasis in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study.
    Yu L; Zhang Z; Yi H; Wang J; Li J; Wang X; Bai H; Ge H; Zheng X; Ni J; Qi H; Guan Y; Xu W; Zhu Z; Xing L; Dekker A; Wee L; Traverso A; Ye Z; Yuan Z
    Radiat Oncol; 2024 Jan; 19(1):10. PubMed ID: 38254106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
    Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS
    Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT.
    Huynh E; Coroller TP; Narayan V; Agrawal V; Romano J; Franco I; Parmar C; Hou Y; Mak RH; Aerts HJ
    PLoS One; 2017; 12(1):e0169172. PubMed ID: 28046060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the performance of both machine learning models using PET and CT radiomics for predicting recurrence following lung stereotactic body radiation therapy: A single-institutional study.
    Nemoto H; Saito M; Satoh Y; Komiyama T; Marino K; Aoki S; Suzuki H; Sano N; Nonaka H; Watanabe H; Funayama S; Onishi H
    J Appl Clin Med Phys; 2024 Jul; 25(7):e14322. PubMed ID: 38436611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.
    Li Q; Kim J; Balagurunathan Y; Qi J; Liu Y; Latifi K; Moros EG; Schabath MB; Ye Z; Gillies RJ; Dilling TJ
    Radiat Oncol; 2017 Sep; 12(1):158. PubMed ID: 28946909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
    Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
    J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiblock Discriminant Analysis of Integrative
    Lee SH; Kao GD; Feigenberg SJ; Dorsey JF; Frick MA; Jean-Baptiste S; Uche CZ; Cengel KA; Levin WP; Berman AT; Aggarwal C; Fan Y; Xiao Y
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1451-1465. PubMed ID: 33662459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of local recurrence and distant metastasis using radiomics analysis of pretreatment nasopharyngeal [18F]FDG PET/CT images.
    Peng L; Hong X; Yuan Q; Lu L; Wang Q; Chen W
    Ann Nucl Med; 2021 Apr; 35(4):458-468. PubMed ID: 33543393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study.
    Kakino R; Nakamura M; Mitsuyoshi T; Shintani T; Kokubo M; Negoro Y; Fushiki M; Ogura M; Itasaka S; Yamauchi C; Otsu S; Sakamoto T; Sakamoto M; Araki N; Hirashima H; Adachi T; Matsuo Y; Mizowaki T
    Med Phys; 2020 Sep; 47(9):4634-4643. PubMed ID: 32645224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment
    Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
    Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.
    Tyran M; Charrier N; Darreon J; Madroszyk A; Tallet A; Salem N
    In Vivo; 2018; 32(1):121-124. PubMed ID: 29275308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.